To investigate the impact of hyperbaric oxygen therapy (HBOT) on the cognitive function of mice with Alzheimer's disease (AD), while also identifying the cellular pathways associated with autophagy involved in the treatment. Twenty-four APP/PSl double transgenic mice were randomly assigned to either Group A or Group B, while another 24 C57 mice were randomly allocated to Group C or Group D. HBOT was administered to mice in Group B and Group D, and the Morris water maze test was used to assess changes in mice behavior. Histological examination using hematoxylin and eosin staining was conducted to observe pathological alterations in the hippocampus of the mice brain tissue. Polymerase chain reaction (PCR) was employed to analyze autophagy-related gene pathways in the hippocampus of the mice. Following HBOT, mice in Group B exhibited a significant reduction in escape latency and a notable increase in residence time within the target quadrant compared with Group A (P<0.05), as well as Group C and Group D (P<0.01). The hippocampal neurons in Group A and Group B mice exhibited disorganized arrangements, characterized by pyknosis and margination. Conversely, neurons in Group C displayed orderly arrangements, retaining intact structures with round nuclei demonstrating clear nuclear staining and normal morphology. The cellular morphology of mice in Group D remained unaffected. PCR analysis revealed no notable disparity in autophagy-related gene expression between Group A and Group C. However, the expression levels of five genes including Tgfb1, Mapk14, Bid, Atg7, and Akt1, were significantly elevated in Group B compared to Group A. HBOT has the potential to improve the cognitive function in mice modeled with AD. This improvement of cognitive function appears to be mediated by the up-regulation of autophagy-related genes, specifically Tgfb1, Mapk14, Bid, Atg7, and Akt1. These results indicate that HBOT may offer a therapeutic strategy for treating AD by enhancing autophagy mechanisms. Key words Alzheimer's disease, Autophagy, Hyperbaric oxygen, Morris water maze, PCR.

Department of Rehabilitation Medicine The Affiliated Haikou Hospital of Xiangya Medical College Central South University No 43 Renmin Avenue Meilan District Haikou 570208 Hainan China and

Zobrazit více v PubMed

Ossenkoppele R, van der Kant R, Hansson O. Tau biomarkers in Alzheimer’s disease: towards implementation in clinical practice and trials. Lancet Neurol. 2022;21:726–734. doi: 10.1016/S1474-4422(22)00168-5. PubMed DOI

Villain N, Planche V, Levy R. High-clearance anti-amyloid immunotherapies in Alzheimer’s disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects. Revue Neurol (Paris) 2022;178:1011–1030. doi: 10.1016/j.neurol.2022.06.012. PubMed DOI

Spenceley S, Caspar S, Pijl E. Mitigating Moral Distress in Dementia Care: Implications for Leaders in the Residential Care Sector. World Health Popul. 2019;18:47–60. doi: 10.12927/whp.2019.26059. PubMed DOI

Xu L, Ding Y, Ma F, Chen Y, Chen G, Zhu L, Long J, Ma R, Liu Y, Liu J. Engineering a pathological tau-targeted nanochaperone for selective and synergetic inhibition of tau pathology in Alzheimer’s Disease. Nano Today. 2022;43:101388. doi: 10.1016/j.nantod.2022.101388. DOI

Zhang F, Niu L, Li S, Le W. Pathological Impacts of Chronic Hypoxia on Alzheimer’s Disease. ACS Chem Neurosci. 2019;10:902–909. doi: 10.1021/acschemneuro.8b00442. PubMed DOI

Chen J, Zhang F, Zhao L, Cheng C, Zhong R, Dong C, Le W. Hyperbaric oxygen ameliorates cognitive impairment in patients with Alzheimer’s disease and amnestic mild cognitive impairment. Alzheimers Dement (N Y) 2020;6:e12030. doi: 10.1002/trc2.12030. PubMed DOI PMC

Shapira R, Gdalyahu A, Gottfried I, Sasson E, Hadanny A, Efrati S, Blinder P, Ashery U. Hyperbaric oxygen therapy alleviates vascular dysfunction and amyloid burden in an Alzheimer’s disease mouse model and in elderly patients. Aging (Albany NY) 2021;13:20935–20961. doi: 10.18632/aging.203485. PubMed DOI PMC

Shapira R, Solomon B, Efrati S, Frenkel D, Ashery U. Hyperbaric oxygen therapy ameliorates pathophysiology of 3xTg-AD mouse model by attenuating neuroinflammation. Neurobiol Aging. 2018;62:105–119. doi: 10.1016/j.neurobiolaging.2017.10.007. PubMed DOI

Huang X. Hyperbaric Oxygen Therapy for Alzheimer’s Disease. EC Pharmacol Toxicol. 2018;6:74–75. PubMed PMC

Shapira R, Efrati S, Ashery U. Hyperbaric oxygen therapy as a new treatment approach for Alzheimer’s disease. Neural Regen Res. 2018;13:817–818. doi: 10.4103/1673-5374.232475. PubMed DOI PMC

Yang C, Yang Q, Xiang Y, Zeng XR, Xiao J, Le WD. The neuroprotective effects of oxygen therapy in Alzheimer’s disease: a narrative review. Neural Regen Res. 2023;18:57–63. doi: 10.4103/1673-5374.343897. PubMed DOI PMC

Guo Y, Li S, Zeng LH, Tan J. Tau-targeting therapy in Alzheimer’s disease: Critical advances and future opportunities. Ageing Neur Dis. 2022;2:11. doi: 10.20517/and.2022.16. DOI

Haake A, Nguyen K, Friedman L, Chakkamparambil B, Grossberg GT. An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease. Expert Opin Drug Saf. 2020;19:147–157. doi: 10.1080/14740338.2020.1721456. PubMed DOI

Hentia C, Rizzato A, Camporesi E, Yang Z, Muntean DM, Săndesc D, Bosco G. An overview of protective strategies against ischemia/reperfusion injury: The role of hyperbaric oxygen preconditioning. Brain Behav. 2018;8:e00959. doi: 10.1002/brb3.959. PubMed DOI PMC

Yang C, Liu G, Zeng X, Xiang Y, Chen X, Le W. Therapeutic effects of long-term HBOT on Alzheimer’s disease neuropathologies and cognitive impairment in APPswe/PS1dE9 mice. Redox Biol. 2024;70:103006. doi: 10.1016/j.redox.2023.103006. PubMed DOI PMC

Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006;12:856–861. doi: 10.1038/nm1438. PubMed DOI PMC

Chuanfen L, Xiaoling W, Wen J, Bingzhen C, Min W. HtrA1L364P leads to cognitive dysfunction and vascular destruction through TGF-β/Smad signaling pathway in CARASIL model mice. Brain Behav. 2022;12:e2691. doi: 10.1002/brb3.2691. PubMed DOI PMC